Security
INSM · INSMED Inc
INSMNASDAQCommon stockCurrentCIK 1104506Updated Sep 26, 2026
INSM price & chart
Loading TradingView…
NASDAQ:INSM on TradingView ↗About the company
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines - including two approved therapies to treat chronic, debilitating lung diseases - as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.
In the news
Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update News provided by Insmed Incorporated Oct 30, 2025, 07:00 ET Share this article Share to X Share this article Share to X —BRINSUPRI ™ (brensocatib ) Approved by FDA as First and Only Treatment for Non-Cystic Fibrosis B ↗
Recent filings
Show 5 more recent filings
144 filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
144 filing
Regulation FD Disclosure
Items 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 2,264,558,000Source | 2,025,231,000Source | 1,329,837,000Source | 1,656,435,000Source |
| Property, Plant and Equipment, NetUSD | 102,942,000Source | 80,052,000Source | 65,384,000Source | 56,491,000Source |
| GoodwillUSD | 136,110,000Source | 136,110,000Source | 136,110,000Source | 136,110,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 510,445,000Source | 555,030,000Source | 482,374,000Source | 1,074,036,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 140,857,000Source | 52,012,000Source | 41,189,000Source | 29,713,000Source |
| Inventory, NetUSD | 132,068,000Source | 98,578,000Source | 83,248,000Source | 69,922,000Source |
| Assets, CurrentUSD | 1,794,208,000Source | 1,621,661,000Source | 929,063,000Source | 1,273,383,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 91,236,000Source | 37,245,000Source | 24,179,000Source | 25,468,000Source |
| Operating Lease, Right-of-Use AssetUSD | 20,708,000Source | 17,257,000Source | 18,017,000Source | 21,894,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,525,582,000Source | 1,739,852,000Source | 1,661,760,000Source | 1,568,484,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 2,143,000Source | 1,794,000Source | 1,480,000Source | 1,357,000Source |
| Additional Paid in CapitalUSD | 6,372,064,000Source | 4,645,791,000Source | 3,113,487,000Source | 2,782,416,000Source |
| Retained Earnings (Accumulated Deficit)USD | -5,636,692,000Source | -4,359,917,000Source | -3,446,145,000Source | -2,696,578,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 1,461,000Source | -2,289,000Source | -745,000Source | 756,000Source |
| Stockholders' Equity Attributable to ParentUSD | 738,976,000Source | 285,379,000Source | -331,923,000Source | 87,951,000Source |
| Liabilities and EquityUSD | 2,264,558,000Source | 2,025,231,000Source | 1,329,837,000Source | 1,656,435,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 468,874,000Source | 297,528,000Source | 225,629,000Source | 190,243,000Source |
| Operating Lease, Liability, CurrentUSD | 9,469,000Source | 9,358,000Source | 8,032,000Source | 6,909,000Source |
| Accounts Payable, CurrentUSD | 79,907,000Source | 73,033,000Source | 65,393,000Source | 50,461,000Source |
| Operating Lease, Liability, NoncurrentUSD | 12,174,000Source | 9,112,000Source | 11,013,000Source | 14,853,000Source |
| Other Liabilities, NoncurrentUSD | 5,646,000Source | 499,000Source | 3,145,000Source | 9,387,000Source |
| Additional Financial Items | ||||
| Deferred Tax Liabilities, NetUSD | 29,000Source | 55,000Source | 85,000Source | 139,000Source |
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 540,964,000Source | 1,103,382,000Source | 1,155,313,000Source | 1,125,250,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | — | 5,500,000Source | 5,300,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 152,710,000Source | 96,835,000Source | 74,778,000Source | 57,686,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 88,307,000Source | 12,932,000Source | 11,963,000Source | 6,423,000Source |
| Increase (Decrease) in InventoriesUSD | 31,519,000Source | 17,044,000Source | 13,613,000Source | 1,714,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | 44,592,000Source | 15,155,000Source | 50,011,000Source |
| Deferred Income Tax Expense (Benefit)USD | -27,000Source | -29,000Source | -54,000Source | -231,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -935,014,000Source | -683,882,000Source | -536,247,000Source | -400,439,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -64,575,000Source | -583,175,000Source | -223,604,000Source | -34,584,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 32,561,000Source | 21,923,000Source | 13,288,000Source | 9,878,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 954,073,000Source | 1,341,020,000Source | 168,439,000Source | 793,273,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | -601,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -44,585,000Source | 72,656,000Source | -591,662,000Source | 357,254,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 510,445,000Source | 555,030,000Source | 482,374,000Source | 1,074,036,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 55,353,000Source | 40,567,000Source | 35,787,000Source | 10,157,000Source |
| Income Taxes Paid, NetUSD | 4,141,000Source | 2,499,000Source | 1,955,000Source | 1,717,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 931,000Source | -1,307,000Source | -250,000Source | -996,000Source |
| Additional Financial Items | ||||
| Accretion ExpenseUSD | — | — | 0Source | 0Source |
| Amortization of Debt Issuance CostsUSD | 6,216,000Source | 6,884,000Source | 7,320,000Source | 3,991,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 6,216,000Source | 6,884,000Source | — | — |
| Amortization of Intangible AssetsUSD | 6,001,000Source | 5,052,000Source | 5,052,000Source | 5,053,000Source |
| DepreciationUSD | 10,449,000Source | 5,961,000Source | 5,527,000Source | 5,278,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 344,501,000Source | 265,784,000Source |
| GoodwillUSD | 136,110,000Source | 136,110,000Source | 136,110,000Source | 136,110,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | 0Source | 0Source | — | — |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | 0Source | 0Source | — | — |
| Income Tax Expense (Benefit)USD | 5,026,000Source | 3,707,000Source | 2,555,000Source | 1,383,000Source |
| InterestExpenseNonoperatingUSD | 83,795,000Source | 84,913,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -1,276,775,000Source | -913,772,000Source | -749,567,000Source | -481,534,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -1,276,775,000Source | -913,772,000Source | -749,567,000Source | -481,534,000Source |
| Operating Lease, ExpenseUSD | 13,600,000Source | 11,900,000Source | 9,200,000Source | 8,000,000Source |
| Other Nonoperating Income (Expense)USD | -1,841,000Source | 29,000Source | 1,856,000Source | -5,939,000Source |
| Proceeds from Issuance of Common StockUSD | 823,282,000Source | 1,084,124,000Source | 152,475,000Source | 292,153,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | 375,000,000Source | 75,000,000Source |
| Proceeds from Stock Options ExercisedUSD | 135,717,000Source | 113,243,000Source | 18,399,000Source | 19,504,000Source |
| Unrealized Gain (Loss) on DerivativesUSD | 0Source | -236,000Source | 320,000Source | -1,526,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 606,423,000Source | 363,707,000Source | 305,208,000Source | 245,358,000Source |
| Cost of RevenueUSD | 122,938,000Source | 85,742,000Source | 65,573,000Source | 55,126,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 701,167,000Source | 461,116,000Source | — | — |
| Operating Income (Loss)USD | -1,246,769,000Source | -878,252,000Source | -709,626,000Source | -457,321,000Source |
| Other Nonoperating Income (Expense)USD | -1,841,000Source | 29,000Source | 1,856,000Source | -5,939,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -1,271,749,000Source | -910,065,000Source | -747,012,000Source | -480,151,000Source |
| Income Tax Expense (Benefit)USD | 5,026,000Source | 3,707,000Source | 2,555,000Source | 1,383,000Source |
| Net Income (Loss) Attributable to ParentUSD | -1,276,775,000Source | -913,772,000Source | -749,567,000Source | -481,534,000Source |
| Earnings Per Share, BasicUSD per share | -6.42Source | -5.57Source | -5.34Source | -3.91Source |
| Earnings Per Share, DilutedUSD per share | -6.42Source | -5.57Source | -5.34Source | -3.91Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 199,014,000Source | 164,043,000Source | 140,433,000Source | 123,035,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 199,014,000Source | 164,043,000Source | 140,433,000Source | 123,035,000Source |
| Interest Expense (non-operating)USD | 83,795,000Source | 84,913,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 6,001,000Source | 5,052,000Source | 5,052,000Source | 5,053,000Source |
| Costs and ExpensesUSD | 1,853,192,000Source | 1,241,959,000Source | 1,014,834,000Source | 702,679,000Source |
| Current Income Tax Expense (Benefit)USD | 5,053,000Source | 3,736,000Source | 2,609,000Source | 1,614,000Source |
| General and Administrative ExpenseUSD | — | — | 344,501,000Source | 265,784,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -1,118,491,000Source | -814,531,000Source | -666,181,000Source | -406,262,000Source |
| Interest ExpenseUSD | 83,795,000Source | 84,913,000Source | 81,694,000Source | 26,446,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -1,276,775,000Source | -913,772,000Source | -749,567,000Source | -481,534,000Source |
| Operating Lease, ExpenseUSD | 13,600,000Source | 11,900,000Source | 9,200,000Source | 8,000,000Source |
| Research and Development ExpenseUSD | 771,093,000Source | 598,367,000Source | 571,011,000Source | 397,518,000Source |
Filing attachments
ef20079469_ex99-1.htm · 8-K · 2026-08-06
EX-99.1 2 ef20079469_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update - Total Company Revenues of $425.5 Million for the Second Quarter of 2026 - - BRINSUPRI® (brensocatib) Revenues of $309.2 Million for the Second Quarter of 2026, Reflecting 49% Growth Over the First Quarter of 2026 - - ARIKAYCE® (amikacin liposome inhalation suspension) Revenues of $116.3 Million for the Second Quarter of 2026, Reflecting 8% Growth O…
Read attachment ↗ef20079469_ex99-2.htm · 8-K · 2026-08-06
EX-99.2 3 ef20079469_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 August 6, 2026 Second-Quarter 2026 Earnings Presentation Forward Looking Statements The forward-looking statements in this presentation are based upon the Company’s current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company’s actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achieve…
Read attachment ↗ef20078093_ex99-1.htm · 8-K · 2026-07-16
EX-99.1 2 ef20078093_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension - 12-Month Data Demonstrated Sustained Improvement with TPIP Across All Secondary Efficacy Measures Including Reduction in Mortality Risk Status by REVEAL Lite 2.0 - - Placebo Crossed Group Demonstrated Treatment Response on TPIP, Achieving Similar Out…
Read attachment ↗ef20078093_ex99-2.htm · 8-K · 2026-07-16
EX-99.2 3 ef20078093_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 July 16, 2026 12-Month Results from Ongoing Open-Label Extension Study of TPIP in PAH Patients TPIP: treprostinil palmitil inhalation powder | PAH: pulmonary arterial hypertension Forward Looking Statements The forward-looking statements in this presentation are based upon the Company's current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results…
Read attachment ↗ef20072589_ex99-1.htm · 8-K · 2026-05-07
EX-99.1 2 ef20072589_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update - Total Company Revenues of $306.0 Million for the First Quarter of 2026 - - BRINSUPRI® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025 - - ARIKAYCE® (amikacin liposome inhalation suspension) Revenues of $98.1 Million for the First Quarter of 2026, Reflecting 6% Growth Over …
Read attachment ↗ef20072589_ex99-2.htm · 8-K · 2026-05-07
EX-99.2 3 ef20072589_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 May 7, 2026 First-Quarter 2026 Earnings Presentation Forward Looking Statements The forward-looking statements in this presentation are based upon the Company’s current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company’s actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievement…
Read attachment ↗